What is Leyden Labs?
Leyden Labs is at the forefront of developing nasal sprays designed to block airborne respiratory viruses at their point of entry. By delivering broadly protective antibodies directly to the respiratory mucosa, the company's approach offers immediate protection where infections begin. These antibody-based nasal sprays hold the potential to safeguard a wide population, including individuals with compromised immune systems, addressing a critical need in public health.
How much funding has Leyden Labs raised?
Leyden Labs has raised a total of $290.2M across 4 funding rounds:
Series A
$45.2M
Series B
$140M
Other Financing Round
$70M
Other Financing Round
$35M
Series A (2021): $45.2M with participation from F-Prime Capital, Brook Byers, Casdin Capital, and GV
Series B (2022): $140M led by SoftBank Group, Byers Capital, GV, Casdin Capital, Invus, Bluebird Ventures, and F-Prime Capital
Other Financing Round (2025): $70M supported by Casdin Capital, Softbank Vision Fund, Qiming Venture Partners, Invus, Bluebird Ventures, F-Prime Capital, ClavystBio, Byers Capital, and Polaris Partners
Other Financing Round (2025): $35M featuring The European Anglers Alliance and Invest-NL
Key Investors in Leyden Labs
SoftBank Group
SoftBank Group Corp. is a global technology holding company driving innovation across telecommunications, internet services, artificial intelligence, smart robotics, IoT, and clean energy technologies. Through its diverse portfolio of companies and strategic investments, including leading semiconductor IP providers, SoftBank Group supports the development and scaling of transformative technologies worldwide.
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors. The company focuses on enterprise solutions, life sciences, consumer products, and frontier technology innovations. GV operates globally with presence across North America, Europe, Asia, and South America, providing financial backing to promising startups and growth-stage businesses.
F-Prime Capital
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies. F-Prime Capital is located in Massachusetts.
What's next for Leyden Labs?
The substantial enterprise-level funding and recent strategic investment indicate Leyden Labs is poised for significant scaling and further research and development. This capital infusion will likely accelerate the company's efforts to bring its protective nasal spray technology to market, potentially expanding its clinical trials and manufacturing capabilities. The strategic nature of the recent financing suggests a focus on market penetration and partnerships to solidify its position in the biopharmaceutical landscape.
See full Leyden Labs company page
